pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Hazard ratio of MACCE in patients on cilostazol or sarpogrelate compared to clopidogrel

Clinical outcomesCilostazol vs. Clopidogrel 5:1 matchingSarpogrelate vs. Clopidogrel 1:1 matching

HR (CI)p-valueHR (CI)p-value
MACCECrude1.25 (0.69-2.29)0.4560.66 (0.30-1.46)0.301
Adjusted1.17 (0.63-2.19)0.6200.88 (0.29-2.61)0.810
DeathCrude0.75 (0.10-5.73)0.7850.71 (0.10-5.15)0.734
Adjusted0.61 (0.08-4.80)0.6420.76 (0.06-9.86)0.836
MICrude1.17 (0.54-2.53)0.6960.37 (0.09-1.46)0.154
Adjusted1.28 (0.56-2.91)0.5580.90 (0.14-5.82)0.909
StrokeCrude1.34 (0.47-3.81)0.5791.12 (0.35-3.57)0.855
Adjusted1.09 (0.37-3.23)0.8740.54 (0.13-2.18)0.388
PVDCrude1.27 (0.39-4.15)0.6882.13 (0.80-5.65)0.129
Adjusted0.86 (0.25-2.93)0.8141.59 (0.38-6.56)0.523

MACCE, major adverse cardiac and cerebrovascular event; MI, myocardial infarction; PVD, peripheral vascular disease; *Adjusted for age, sex, comorbidity, concurrent medications. Crude: before PS matching, Adjusted: after PS matching and adjusted for patient characteristics.

Korean J Clin Pharm 2019;29:254-66 https://doi.org/10.24304/kjcp.2019.29.4.254
© 2019 Korean J Clin Pharm